View in EDS HTML Full Text PDF Full Text

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Saved in:
Bibliographic Details
Title: Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Authors: Egeler, M. D. (AUTHOR), van de Poll-Franse, L. V. (AUTHOR), Tissier, R. (AUTHOR), Rogiers, A. (AUTHOR), Boers-Sonderen, M. J. (AUTHOR), van den Eertwegh, A. J. (AUTHOR), Hospers, G. A. (AUTHOR), de Groot, J. W. B. (AUTHOR), Aarts, M. J. B. (AUTHOR), Kapiteijn, E. (AUTHOR), Piersma, D. (AUTHOR), Vreugdenhil, G. (AUTHOR), van der Veldt, A. A. (AUTHOR), Suijkerbuijk, K. P. M. (AUTHOR), Neyns, B. (AUTHOR), Janssen, K. J. (AUTHOR), Blank, C. U. (AUTHOR), Retèl, V. P. (AUTHOR), Boekhout, A. H. (AUTHOR)
Source: Quality of Life Research. Sep2023, Vol. 32 Issue 9, p2517-2525. 9p. 4 Charts.
Subjects: Melanoma, Quality-adjusted life years, Overall survival
Abstract: Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = −.82, p =.022) and fatigue burden (β = −.29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores. [ABSTRACT FROM AUTHOR]
Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 169703222
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Egeler%2C+M%2E+D%2E%22">Egeler, M. D.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+de+Poll-Franse%2C+L%2E+V%2E%22">van de Poll-Franse, L. V.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tissier%2C+R%2E%22">Tissier, R.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rogiers%2C+A%2E%22">Rogiers, A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boers-Sonderen%2C+M%2E+J%2E%22">Boers-Sonderen, M. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+den+Eertwegh%2C+A%2E+J%2E%22">van den Eertwegh, A. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hospers%2C+G%2E+A%2E%22">Hospers, G. A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22de+Groot%2C+J%2E+W%2E+B%2E%22">de Groot, J. W. B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aarts%2C+M%2E+J%2E+B%2E%22">Aarts, M. J. B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kapiteijn%2C+E%2E%22">Kapiteijn, E.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Piersma%2C+D%2E%22">Piersma, D.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vreugdenhil%2C+G%2E%22">Vreugdenhil, G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+der+Veldt%2C+A%2E+A%2E%22">van der Veldt, A. A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Suijkerbuijk%2C+K%2E+P%2E+M%2E%22">Suijkerbuijk, K. P. M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Neyns%2C+B%2E%22">Neyns, B.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Janssen%2C+K%2E+J%2E%22">Janssen, K. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Blank%2C+C%2E+U%2E%22">Blank, C. U.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Retèl%2C+V%2E+P%2E%22">Retèl, V. P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boekhout%2C+A%2E+H%2E%22">Boekhout, A. H.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Quality+of+Life+Research%22">Quality of Life Research</searchLink>. Sep2023, Vol. 32 Issue 9, p2517-2525. 9p. 4 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Melanoma%22">Melanoma</searchLink><br /><searchLink fieldCode="DE" term="%22Quality-adjusted+life+years%22">Quality-adjusted life years</searchLink><br /><searchLink fieldCode="DE" term="%22Overall+survival%22">Overall survival</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors. Methods: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24–36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24–36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores. Results: Health-state utility scores were similar between the 24–36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p =.22). In survivors, lower utility scores were associated with symptoms of depression (β = −.82, p =.022) and fatigue burden (β = −.29, p =.007). Utility scores did not significantly change after 24–36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p =.07). Discussion: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Quality of Life Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=169703222
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11136-023-03427-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 2517
    Subjects:
      – SubjectFull: Melanoma
        Type: general
      – SubjectFull: Quality-adjusted life years
        Type: general
      – SubjectFull: Overall survival
        Type: general
    Titles:
      – TitleFull: Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Egeler, M. D.
      – PersonEntity:
          Name:
            NameFull: van de Poll-Franse, L. V.
      – PersonEntity:
          Name:
            NameFull: Tissier, R.
      – PersonEntity:
          Name:
            NameFull: Rogiers, A.
      – PersonEntity:
          Name:
            NameFull: Boers-Sonderen, M. J.
      – PersonEntity:
          Name:
            NameFull: van den Eertwegh, A. J.
      – PersonEntity:
          Name:
            NameFull: Hospers, G. A.
      – PersonEntity:
          Name:
            NameFull: de Groot, J. W. B.
      – PersonEntity:
          Name:
            NameFull: Aarts, M. J. B.
      – PersonEntity:
          Name:
            NameFull: Kapiteijn, E.
      – PersonEntity:
          Name:
            NameFull: Piersma, D.
      – PersonEntity:
          Name:
            NameFull: Vreugdenhil, G.
      – PersonEntity:
          Name:
            NameFull: van der Veldt, A. A.
      – PersonEntity:
          Name:
            NameFull: Suijkerbuijk, K. P. M.
      – PersonEntity:
          Name:
            NameFull: Neyns, B.
      – PersonEntity:
          Name:
            NameFull: Janssen, K. J.
      – PersonEntity:
          Name:
            NameFull: Blank, C. U.
      – PersonEntity:
          Name:
            NameFull: Retèl, V. P.
      – PersonEntity:
          Name:
            NameFull: Boekhout, A. H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 09629343
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Quality of Life Research
              Type: main
ResultId 1